Systematization of hypertensive patients based on pathogenetic mechanisms - a way to optimize antihypertensive therapy
https://doi.org/10.18705/1607-419X-2010--2-
Abstract
Objective. To systematize patients with arterial hypertension (AH) according to the pathogenetic mechanisms of its development and response to antihypertensive therapy. Design and methods. Included 896 patients were included (mean age was (M ± m) 54,0 ± 8,0 years, systolic blood pressure (BP) - 196,3 ± 6,4 mmHg, diastolic BP - 115,0 ± 4,8 mmHg). Plasma renin activity (PRA) and plasma aldosterone concentration (PAC) were estimated by radioimmune method at 8-9 hours in the morning while awake state. PRA was rated as normal if ranged 1,0-3,0 ng/ml/h, and PAC - 0, 18-0,83 nmol/l (5-23 ng/dl or 50-230 pg/ml). Conclusions. According to the circulating blood volume, renin-angiotensin-aldosterone and sympathoadrenal system and the response to antihypertensive therapy 16 subgroups of hypertensive patients were formed: 12 of them included patients with essential hypertension, 2 subgroups - with «transitional form of low renin hypertension», and 2 subgroups - with primary hyperaldosteronism.
About the Authors
Sh. V. Akhadov
Clinical Hospital № 154, Moscow
Russian Federation
Russian Federation
G. R. Ruzbanova
Clinical Hospital № 81, Moscow
Russian Federation
Russian Federation
A. Sh. Akhadova
N.I. Pirogov Russia State Medical University, Moscow
Russian Federation
Russian Federation
References
1. Antonaccio M.J., Kerwin L. Pre- and postjunctional inhibition of vascular sympathetic function by captoprill in SHR: implication of vascular angiotensin 2 in hepertension and antihypertension actions of captopril // Hypertension. - 1981. - Vol. 3 (Suppl. 1). - Р. 54- 62.
2.
3. Johnston C.I., Risvanis J. Preclinical pharmacology of angiotensin II receptor antagonists // Am. J. Hypertens. - 1997. - Vol. 10, № 12 (Pt. 2). - P. 306-310.
4.
5. Dzau V.J. Circulating versus local renin-angiotensin system in cardiovascular homeostasis // Circulation. - 1988. - Vol. 77 (Suppl. I). - P. 14-13.
6.
7. Alderman M.H., Ooi W.L., Cohen H. et al. Plasma renin activity; A risk factor for myocardial infartion in hypertensibe patients // Am. J. Hypertens. - 1997. - Vol. 10, № 1. - P. 1-9.
8.
9. Ахадов Ш.В., Рузбанова Г.Р., Молчанова Г.С. и др. Роль и целевой уровень отдельных компонентов ренин-ангиотензин-альдостероновой системы в развитии сердечно-сосудистых осложнений у больных артериальной гипертензией // Рос. кардиол. журн. - 2009. - T. 77, № 3. - C. 26-31.
10.
11. Landsberg L. Hyperinsulinemia: possible role in obesity- induced hypertension // Hypertension. - 1992. - Vol.19 (Suppl.1). - P. 161-166.
12.
13. Landsberg L., Young J.B. Insulin-mediated glucose metabolism in the relationship between dietary intake and sympathetic nervous system activity // Int. J. Obes. - 1985. - Vol. 9 (Suppl. 2). - P. 63-68.
14.
15. Rupp H., Tucano M., Jacob R. Caloric intake and radio telemetrically assessed high blood pressure. 1. Effect of the centrally acting antihypertensive drug moxonidine // Pharmaceut. Pharmacol. Left. - 1993. - Vol. 3. - P. 120-123.
16.
17. Hansen M., Rupp H. Cellular and molecular changes in the heart during stress or exercise // Methods Achieve Exp. Pathol. - 1991. - Vol. 15. - P. 58-83.
18.
19. Messerli F.H. Essential hypertension in the elderly // Triangle. - 1985. - Vol. 24. - P. 25-47.
20.
21. Philipp Th. Sympathisches nervensystem bei essentieller hypertonie: aktivitat und reaktivitat // In: Arterielle Hypertonie / Ed. by J. Rosenthal. - Verlag, Berlin-Heidelberg-New York-Tokyo: Springer, 1986. - P. 50-57.
22.
23. Anderson E.A., Sinkey C.A., Lawton W.J. et al. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings // Hypertension. - 1989. - Vol. 14, № 2. - P. 177-183.
24.
25. Wallin B.G., Morlin C., Hjemdahl P. Muscle sympathetic activity and venous plasma noradrenaline concentrations during static exercise in normotensive and hypertensive subjects // Acta Physiol. Scand. - 1987. - Vol. 129. - P. 489-497.
26.
27. Leimbach W.N. Jr., Wallin B.G., Victor R.G. et al. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure // Circulation. - 1986. - Vol. 73, № 5. - P. 913-919.
28.
29. Swedberg K., Eneroth P., Kjekshus J. et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group // Circulation. - 1990. - Vol. 82, № 5. - P. 1730-1736.
30.
31. Held P.H., Yusuf S., Furberg C.D. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview // Br. Med. J. - 1989. - Vol. 299, № 6709. - P. 1187-92.
32.
33. McCance A.J., Forfar J.C. Cardiac and whole body [3H]noradrenaline kinetics in ischaemic heart disease: contrast between unstable anginal syndromes and pacing induced ischaemia // Br. Heart J. - 1989. - Vol. 61, № 3. - P.238-47.
34.
35. The Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiolody. 2007 Guidelines for the management of arterial hypertension // J. Hypertens. - 2007. - Vol. 25, № 6. - P. 1105-1187.
36.
37. Devereux R.B., Reichek N. Echocardiographic determination of left ventricular mass in men. Anatomic validation of the method // Circulation. - 1977. - Vol. 55, № 4. - P.613-618.
38.
39. European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. Guidelines Committee // J. Hypertens. - 2003. - Vol. 21, № 6. - P. 1011-1053.
40.
41. Вoudein-Legras M., Coloix J., Grabes M. et al. Handbook of hypertension // New York. - 1986. - Vol. 8. - P. 670-686.
42.
43. Blaustein M.P., Hamlyn J.M. Role of natriuretic factor in essential hypertension: a hypothesis // Ann. J. Intern. Med. - 1983. - Vol. 98, № 5 (Pt. 2). - P. 785-790.
44.
45. Rubin R.P. The role of calcium in the release of neurotransmitter substances of hormones // Pharmacol. Rev. - 1970. - Vol. 22, № 3. - P. 389-427.
46.
47. Morgenroth V.H., Boadle-Biber M., Roth R.H. Tyrosin hydroxylase: activation by nerve stimulation // Proc. Natl. Acad. Sci. USA. - 1974. - Vol. 71, № 11. - P. 4283-4287.
48.
49. Blaustein M.P., Hamlyn I.M. Sodium transport in hypertension // Am. J. Med. - 1984. - Vol. 77, № 4А. - P. 45-49.
50.
51. Johansson B. Vascular smooth muscle reactivity // Ann. Rev. Physiol. - 1981. - Vol. 43. - P. 359-370.
52.
53. Ахадов Ш.В., Рузбанова Г.Р., Ахадова А.Ш. Влияние оригинального эналаприла Ренитек на ренин-ангиотензин-альдостероновую и симпатоадреналовую систему у больных артериальной гипертензией // Артериальная гипертензия. - 2010. - T. 16, № 1. - C. 66-73.
54.
55. Ахадов Ш.В., Рузбанова Г.Р., Молчанова Г.С. Эволюционные стадии низкорениновой артериальной гипертонии // Рациональная фармакотерапия в кардиологии. - 2010. - T. 6, № 1. - C. 68-72.
56.
57. Оhya Y., Sperelakis N. Involvement of a GTP-linding protein in stimulating action of angiotensin- on calcium channels in vascular smooth muscle cells // Circ. Res. - 1991. - Vol. 68, № 3. - P. 763-771.
58.
59. Schelling P., Fischer H., Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy? // J. Hypertens. - 1991. - Vol. 9, № 1. - P. 3-15.
60.
61. Ахадов Ш.В., Рузбанова Г.Р. Особенности действия оргинального эналаприла Ренитек в моно-и комбинированной терапии на ренин-ангиотензин-альдостероновую систему у больных низкорениновой артериальной гипертензией // Артериальная гипертензия. - 2009. - T. 15, № 6. - C. 671-678.
62.
63. Ахадов Ш.В., Рузбанова Г.Р., Молчанова Г.С. и др. Изменения активности ренин-ангиотензин-альдостероновой и симпатоадреналовой систем при прогрессировании артериальной гипертензии // Кардиоваск. тер. профилактика. - 2010. - T. 9, № 2. - C.10-15.
64.
65. Fogari R., Zoppi A., Malamini G.D. et al. Ambulatory blood pressure monitoring in normotensive and hypertensive type 2 diabetics. Prevalence of impaired diurnal blood pressure patterns // Am. J. Hypertens. - 1993. - Vol. 6, № 1. - P. 1-7.
66.
67. Goldberg R.J., Larson M., Levy D. Factors associated with survival to 75 years of age in middle-aged men and women // Arch. Intern. Med. - 1996. - Vol. 156, № 5. - P. 505-509.
68.
69. Kannel W.B. Office assessment of coronary candidates and risk factor insights from the Framingham study // J. Hypertension. - 1991. - Vol. 9 (Suppl.). - P. 13-19.
70.
71. Janssen I., Katzmarzyk P., Church T.S. et al. The Cooper clinic mortality risk index. Clinical score sheet for men // Am. J. Prev. Med. - 2005. - Vol. 29, № 3. - P. 194-203.
72.
73. Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Eur. Heart J. - 2007. - Vol. 28, № 12. - P. 1462-1536. 38. The BEAUTIFUL Study Group. The BEAUTIFUL Study/Randomized trial of Ivabradine in patients with stable coronary artery disease and left ventricular dysfunction- baseline characteristics of the study population cardiology // Cardiology. - 2008. - Vol. 110, № 4. - P. s271-s282.
74.
75. Ахадов Ш.В., Рузбанова Г.Р., Молчанова Г.С. и др. Оценка активности и клиническое значение симпатоадреналовой системы у больных артериальной гипертензией // Рос. кардиол. журн. - 2009. - Т. 2, № 76. - С. 13-17.
Review
For citations:
Akhadov Sh.V., Ruzbanova G.R., Akhadova A.Sh. Systematization of hypertensive patients based on pathogenetic mechanisms - a way to optimize antihypertensive therapy. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2010;16(2):191-201. (In Russ.) https://doi.org/10.18705/1607-419X-2010--2-
Views:
571
Email this article 